Twenty-six percent of people who are taking a wait-and-see approach about whether to get the COVID-19 vaccine say that they’d be more likely to get vaccinated if it involved just a single dose.
As a panel of experts for the US Food and Drug Administration today reviews the data from clinical trials of Janssen’s single-dose vaccine for coronavirus disease 2019 (COVID-19), they may want to also consider how approval of a single-dose vaccine might play with the public. According to a report by the KFF COVID-19 Vaccine Monitor, a single-dose vaccine would nudge some Americans who are now hesitant about getting vaccinated toward getting the shot.
The report also finds that there’s more acceptance to getting the COVID-19 vaccine in general: 55% of Americans have either gotten their first shot of a vaccine or say that they want to get vaccinated as soon as possible. That’s an increase from the 47% who said the same thing in mid-January and the 34% who said the same thing in December.
However, 22% of respondents say that they will definitely not get vaccinated unless they have to in order to keep their jobs, or stay in school, or participate in other activities that they want to participate in but that require vaccination.
But even here, there may be an opportunity for overcoming vaccine hesitancy. The report says that 26% of those in the wait-and-see group say that they would be more likely to get the vaccine if it’s just one dose.
Source: KFF COVID-19 Vaccine Monitor
The survey of 1874 persons, conducted from February 15 to 23, includes oversamples of about 500 Blacks and 500 Hispanics. Thirty-four percent of Blacks and 26% of Hispanics who are 18 to 29 years old say that they will wait and see how the vaccine works for everybody else before they get it. Eighteen percent of White adults in the that age group say that they will wait and see.
Source: KFF COVID-19 Vaccine Monitor
Fear of side effects continues to be the main reason for vaccine hesitancy with 56% of those who “have not yet been vaccinated, including 80% of those in the ‘wait and see’ group, say they are ‘very concerned’ or ‘somewhat concerned’ that they might experience serious side effects from the vaccine,” the survey states.
Source: KFF COVID-19 Vaccine Monitor
Any American who wants the vaccine can get the vaccine at no cost, but apparently not everyone has gotten the news. About half of those in the wait-and-see group worry that they may have to pay for it. Also a factor in that group: fear that the side effects might make them miss work and concern that the vaccine might actually give them COVID-19.
As has been much noted and commented on, wanting the vaccine and getting the vaccine are two different things. “Most U.S. adults who have not yet gotten vaccinated (94% of all adults) say they do not have enough information about when and where to get a COVID-19 vaccine once they are eligible,” the report states. “This includes six in ten Black and Hispanic adults who say they don’t have enough information about where to get the vaccine.”
Source: KFF COVID-19 Vaccine Monitor
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.